Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Americas
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of NHL comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key NHL patient populations covering 171 countries and more than 99% of…
Acute Lymphoblastic Leukemia – Current Treatment – Acute Lymphoblastic Leukemia | Current Treatment: Physician Insights | US
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…
Immune Thrombocytopenic Purpura | Treatment Algorithms: Claims Data Analysis | US
Immune thrombocytopenia purpura (ITP) is an autoimmune form of acquired thrombocytopenia that leads to a decrease in platelet production and an increased risk of bleeding. Current therapies for ITP…
Hemolytic Disease of the Fetus and Newborn – Executive Insights – Hemolytic Disease of the Fetus and Newborn | Executive Insights | US/EU5
Hemolytic disease of the fetus and newborn (HDFN), also known as alloimmune HDFN or erythroblastosis fetalis, is a rare red blood cell disorder in which maternal antibodies attack the red blood…
